Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

Open access
Marubayashi, Sachie, Koppikar, Priya, Taldone, Tony, Abdel-Wahab, Omar, West, Nathan, Bhagwat, Neha, Caldas-Lopes, Eloisi, Ross, Kenneth N., Gönen, Mithat, Gozman, Alex, Ahn, James H., Rodina, Anna, Ouerfelli, Ouathek, Yang, Guangbin, Hedvat, Cyrus, Bradner, James E., Chiosis, Gabriela, Levine, Ross L. · 2010 · Journal of Clinical Investigation

Abstract

JAK2 kinase inhibitors were developed for the treatment of myeloproliferative neoplasms (MPNs), following the discovery of activating JAK2 mutations in the majority of patients with MPN. However, to date JAK2 inhibitor treatment has shown limited efficacy and apparent toxicities in clinical trials. We report here that an HSP90 inhibitor, PU-H71, demonstrated efficacy in cell line and mouse models of the MPN polycythemia vera (PV) and essential thrombocytosis (ET) by disrupting JAK2 protein stability. JAK2 physically associated with both HSP90 and PU-H71 and was degraded by PU-H71 treatment in vitro and in vivo, demonstrating that JAK2 is an HSP90 chaperone client. PU-H71 treatment caused potent, dose-dependent inhibition of cell growth and signaling in JAK2 mutant cell lines and in primary MPN patient samples. PU-H71 treatment of mice resulted in JAK2 degradation, inhibition of JAK-STAT signaling, normalization of peripheral blood counts, and improved survival in MPN models at doses that did not degrade JAK2 in normal tissues or cause substantial toxicity. Importantly, PU-H71 treatment also reduced the mutant allele burden in mice. These data establish what we believe to be a novel therapeutic rationale for HSP90 inhibition in the treatment of JAK2-dependent MPN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci42442

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 184

Metadata

Authors
Marubayashi, S., Koppikar, P., Taldone, T., Abdel-Wahab, O., West, N., Bhagwat, N., Caldas-Lopes, E., Ross, K. N., Gönen, M., Gozman, A., Ahn, J. H., Rodina, A., Ouerfelli, O., Yang, G., Hedvat, C., Bradner, J. E., Chiosis, G., & Levine, R. L.
Venue
Journal of Clinical Investigation
Published
2010-10-01
Volume
120
Issue
10
Pages
3578-3593
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2168586801
Cited by
184
References
4
FWCI
8.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. https://app.cochat.ai/papers/10.1172/jci42442
The paper
Marubayashi, S., Koppikar, P., Taldone, T., Abdel-Wahab, O., West, N., Bhagwat, N., Caldas-Lopes, E., Ross, K. N., Gönen, M., Gozman, A., Ahn, J. H., Rodina, A., Ouerfelli, O., Yang, G., Hedvat, C., Bradner, J. E., Chiosis, G., & Levine, R. L. (2010). HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. Journal of Clinical Investigation. https://doi.org/10.1172/jci42442

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.